Research Article | Open Access
Jianglin Zheng, Xuan Wang, Yue Qiu, Minjie Wang, Hao Yu, Zijie Zhou, Zhipeng Wu, Xiaobing Jiang, "Identification of Critical m6A RNA Methylation Regulators with Prognostic Value in Lower-Grade Glioma", BioMed Research International, vol. 2021, Article ID 9959212, 17 pages, 2021. https://doi.org/10.1155/2021/9959212
Identification of Critical m6A RNA Methylation Regulators with Prognostic Value in Lower-Grade Glioma
Increasing evidences have revealed that N6-methyladenosine (m6A) RNA methylation regulators participate in the tumorigenesis and development of multiple tumors. So far, there has been little comprehension about the effects of m6A RNA methylation regulators on lower-grade gliomas (LGG). Here, we systematically investigated the expression profiles and prognostic significance of 36 m6A RNA methylation regulators in LGG patients from the TCGA and CGGA databases. Most of the m6A RNA methylation regulators are differentially expressed in LGG tissues as compared with normal brain tissues and glioblastoma (GBM) tissues. The consensus clustering for these m6A RNA methylation regulators identified three clusters. Patients in cluster 3 exhibited worse prognosis. In addition, we constructed an m6A-related prognostic signature, which exhibited excellent performance in prognostic stratification of LGG patients according to the results of the Kaplan-Meier curves, ROC curves, and univariate and multivariate Cox regression analyses. In addition, a significant correlation was observed between the m6A-related prognostic signature and the immune landscape of the LGG microenvironment. The high-risk group exhibited higher immune scores, stromal scores, and ESTIMATE scores but lower tumor purity and lower abundance of activated NK cells. Moreover, the expression level of immune checkpoints was positively correlated with the risk score. To conclude, the current research systematically demonstrated the prognostic roles of m6A RNA methylation regulators in LGG.
Gliomas constitute the frequent intracranial malignant tumors, showing significant heterogeneity with respect to tumor biological behavior for different grade gliomas [1, 2]. Despite the less malignancy of low-grade gliomas (LGG) compared with glioblastomas (GBM), tumor recurrence and malignant progression seem to be ineluctable for LGG patients even with the standard treatments, including surgical resection, radiotherapy, and chemotherapy . So far, we have made a considerable advance in understanding the genetic landscape of LGG, and favorable treatment options remain insufficient. Hence, exploring new prognostic biomarkers or treatment targets is of great clinical significance for LGG patients.
RNA modification is an emerging field of epigenetics. Among more than 150 RNA modifications, N6-methyladenosine (m6A) constitutes the most frequent type in eukaryotes [4, 5] and is critically important for gene expression regulation [6, 7]. As a reversible and dynamic process, m6A RNA methylation is regulated by m6A RNA methylation regulators, including methyltransferases, demethylases, and binding proteins, namely, “writers”, “erasers”, and “readers”, respectively. Increasing evidences have suggested that m6A modification contributes to the malignant biological behavior of multiple cancers [8, 9]. The prognostic value of m6A RNA methylation regulators has also been confirmed in head and neck squamous cell carcinoma , thyroid carcinoma , breast cancer , hepatocellular carcinoma , gastric cancer , etc. However, no literatures have comprehensively evaluated the prognostic role of m6A RNA methylation regulators in LGG.
Here, the expression profile and prognostic significance of 36 m6A RNA methylation regulators were systematically evaluated in LGG using the data from The Cancer Genome Atlas (TCGA) dataset and Chinese Glioma Genome Atlas (CGGA) dataset. In addition, we constructed an m6A-related prognostic signature with robust ability in predicting survival outcomes of LGG patients.
2. Materials and Methods
2.1. Data Acquisition
Total 1013 LGG patients with RNA-seq transcriptome data and corresponding clinicopathological features were identified in public databases, including 423 cases from the TCGA dataset and 590 cases from the CGGA dataset. Patients without survival information or OS <30 days, or without definitive histopathological diagnosis had been excluded from further evaluation. These two datasets were used as the training cohort (TCGA) and validation cohort (CGGA). The RNA-seq transcriptome data of 160 GBM tissues and 1152 normal brain tissues were obtained from the TCGA dataset and the Genotype-Tissue Expression (GTEx) database, respectively. All RNA-seq transcriptome data were harmonized using quantile normalization and SVAseq-based batch effect removal . The clinicopathological features of included LGG patients were summarized in Table 1.
2.2. Screening of m6A RNA Methylation Regulators with Differential Expression Profiles
According to published articles and reviews [16, 17], thirty-six m6A RNA methylation regulators with obtainable expression data were identified in the TCGA, CGGA, and GTEx datasets (Table 2). The expression of these 36 m6A RNA methylation regulators was compared in LGG tissues with normal brain tissues and glioblastoma tissues and with different WHO grades.
2.3. Consensus Clustering
Interactions among m6A RNA methylation regulators were analyzed utilizing the STRING database. Using the R package “ConsensusClusterPlus” , distinct clusters of LGG patients were identified based on the expression levels of 36 m6A RNA methylation regulators. Principal Component Analysis (PCA) was performed to confirm the reliability of clustering results . The differentially expressed genes (DEGs) in different clusters were determined ( and adjusted ) and functionally annotated by the Gene Ontology (GO) analysis and the Kyoto Encyclopedia of genes and Genomes (KEGG) pathway analysis.
2.4. Construction and Validation of the m6A-Related Prognostic Signature
Univariate Cox regression was performed to identify the overall survival- (OS-) associated m6A RNA methylation regulators (), which were subsequently incorporated into the least absolute shrinkage and selection operator (LASSO) Cox regression. A total of nine m6A RNA methylation regulators with LASSO coefficients were identified. The calculation formula of risk score is shown below:where and refer to the expression level of selected m6A RNA methylation regulator and corresponding LASSO coefficient, respectively. The median risk score was used for the high-/low-risk grouping of LGG patients. The Kaplan-Meier curve with log-rank test was generated by using the R package “survminer” for the comparison of OS between the high- and low-risk groups. The ROC curve analysis was utilized to evaluate the prediction accuracy of the m6A-related prognostic signature via the R package “timeROC”. All these tests were performed simultaneously in the training and validation cohorts.
2.5. Establishment and Evaluation of a Nomogram
By employing the R package “rms”, “regplot”, and “Hmisc”, a nomogram was established based on the independent prognostic indicators in the training cohort, which were determined through univariate and multivariate Cox regression analyses. The availability of this nomogram was evaluated by the C-indices  and calibration curves.
2.6. Evaluation of the Immune Landscape
The immune scores, stromal scores, ESTIMATE scores, and tumor purity of each LGG patients were calculated using the ESTIMATE algorithm via the R package “estimate” . The abundance of 22 immune cells was calculated through the CIBERSORT algorithm with 1,000 permutations . Patients with CIBERSORT were excluded from the subsequent analysis.
2.7. Statistical Analysis
The preprocessing of RNA-seq transcriptome data was performed using the PERL programming language (version 5.32.0). The R software (version 4.0.2) was applied for all statistical analyses and graph visualization. The student -test or one-way ANOVA test was utilized to compare the continuous variables with normal distribution between two groups or more than two groups. The Wilcoxon test was performed to determine the differences between subgroups in the expression levels of m6A RNA methylation regulators and the abundance of 22 immune cells. The “Spearman” method was used to calculate the correlations between the expression of m6A RNA methylation regulators and between the expression of immune checkpoints and risk scores. Two-tailed was considered statistically significant.
3.1. The Expression Profiles of m6A RNA Methylation Regulators in LGG
Among 36 m6A RNA methylation regulators, twenty-two upregulated genes and eleven downregulated genes were identified in LGG tissues compared with normal brain tissues (Figure 1(a)). Compared with GBM tissues, the expression levels of 16 m6A RNA methylation regulators were upregulated, while the expression levels of 15 m6A RNA methylation regulators were downregulated in LGG tissues (Figure 1(b)). In addition, there were also large variations in the expression profiles of m6A RNA methylation regulators between different histological grades. A total of 22 m6A RNA methylation regulators were differentially expressed between WHO grade II and III (Figure 1(c)). Altogether, these results suggested that the m6A RNA methylation regulators may play a vital and particular role in the tumorigenesis and progression of LGG.
The interactions among 36 m6A RNA methylation regulators were presented in the protein-protein interaction (PPI) network and coexpression analyses. Noticeably, “writers” had a wide range of interactions with other m6A RNA methylation regulators, while “erasers” were less connected with others (Figure 2(a)). Further coexpression analyses showed most m6A RNA methylation regulators were positively correlated with other regulators, and negative coexpression relationships were underrepresented (Figure 2(b)).
3.2. Three Clusters of LGG Patients with Distinct Prognosis
According to the similarity in 36 m6A RNA methylation regulators expression and the proportion of ambiguous clustering measure, was picked as the most appropriate value in the TCGA cohort (Figure 2(c) and Supplementary Figure S1). As a result, 423 LGG patients were categorized into three clusters, called cluster 1 (), cluster 2 (), and cluster 3 (). PCA for total transcriptomic data revealed prominent differences in distribution among three clusters, which confirmed the validity of consensus clustering (Figure 2(d)). Then, the survival analysis showed patients in cluster 3 had obviously shorter OS than those in cluster 1 and cluster 2 (Figure 2(e)). To identify the different biological processes in cluster 3 compared with cluster 1 and cluster 2, a total of 303 upregulated overlapping DEGs were identified in cluster 3 (Figure 2(f)) and were functionally annotated by the GO and KEGG pathway analyses. The results indicated that upregulated DEGs were enriched in an extracellular matrix organization, regulation of vasculature development, regulation of angiogenesis, and nuclear division, which were malignancy-related biological processes (Figure 2(g)). Then, the KEGG pathway analysis similarly exhibited the significant enrichment of malignancy-related pathways, including PI3K-Akt pathway, focal adhesion, proteoglycans in cancer, and ECM-receptor interaction (Figure 2(h)).
3.3. Construction and Validation of the m6A-Related Prognostic Signature
Based on the results of Univariate Cox regression, fourteen m6A RNA methylation regulators (RBM15, ALKBH5, ALKBH3, ZCCHC4, SETD2, HNRNPA2B1, IGF2BP2, IGF2BP3, YTHDC1, YTHDC3, YTHDF1, YTHDF2, SRSF10, and EIF3H) were significantly associated with the OS of LGG patients (Figure 3(a)). Subsequently, the LASSO Cox regression for those 14 m6A RNA methylation regulators was carried out (Figures 3(b) and 3(c)). A total of 9 m6A RNA methylation regulators (ZCCHC4, SETD2, IGF2BP2, IGF2BP3, YTHDF2, RBM15, ALKBH3, EIF3H, and YTHDC1) stood out as the bases of constructing the m6A-related prognostic signature (Figure 3(d)). The risk score for each LGG patient was calculated by summing the product of the expression level of each selected m6A RNA methylation regulator and corresponding LAASO coefficient. The median risk score was applied to stratify LGG patients into high-/low-risk groups.
The prognostic value of the m6A-related prognostic signature for LGG patients was evaluated in the TCGA cohort and the CGGA cohort, respectively. The Kaplan-Meier curves showed that patients in the high-risk group exhibited shorter OS than those in the low-risk group (Figures 4(a) and 4(b)). The distribution plots of the risk score and survival status revealed that the higher the risk score, the more deaths of LGG patients (Figures 4(c) and 4(d)). Moreover, the high accuracy of this m6A-related prognostic signature in predicting 1-, 3-, and 5-year OS was confirmed by the area under the receiver operating characteristic (ROC) curve (AUC). The AUCs of 1-, 3-, and 5-year OS in the TCGA cohort were 0.882, 0.847, and 0.757, respectively (Figure 4(e)), and in the CGGA cohort were 0.780, 0.768, and 0.753, respectively (Figure 4(f)). Overall, the above results all agreed that the m6A-related prognostic signature could accurately and stably predict the survival outcome of LGG patients.
3.4. Associations between the Risk Score and Clinicopathological Features
The levels of risk scores were compared between LGG patients stratified by various clinicopathological features. The results demonstrated that LGG patients with the clinicopathological features of age ≥45 years, more malignant histological type (anaplastic oligodendroglioma/oligoastrocytoma), higher WHO grade, IDH wide type, 1p19q noncodel, and MGMT promoter unmethylated showed significantly higher levels of risk score, while no risk score differences were observed between patients satisfied by gender (Figure 5(a)). To determine whether the prediction power of the m6A-related prognostic signature retains in various subgroups, we performed subgroup survival analyses based on clinicopathological features (Figure 5(b)). The worse OS was noted in the high-risk groups regardless of age, gender, grade, and MGMT promoter status. Furthermore, patients with higher risk still had shorter OS than those with lower risk in the WHO grade III, anaplastic astrocytoma, anaplastic oligodendroglioma/oligoastrocytoma, IDH wide type, and 1p19q noncodel subgroups, except for the WHO grade II, astrocytoma, oligodendroglioma/oligoastrocytoma, IDH mutant, and 1p19q codel subgroups.
3.5. Establishment and Evaluation of a Nomogram Based on Independent Prognostic Indicators for OS
To identify the independent prognostic indicators for OS, the OS-related factors identified by univariate Cox regression analyses were subsequently analyzed using multivariate Cox regression. The signature-based risk score was an independent prognostic indicator for OS in both TCGA and CGGA cohorts (both ; Figures 6(a) and 6(b)). Then, a nomogram was established based on the independent prognostic indicators (age, 1p19q, and Risk score) in the TCGA cohort (Figure 7(a)). The C-indices of this nomogram were in the TCGA cohort and in the CGGA cohort. The calibration plots showed a perfect fit between the actual and nomogram-predicted probability of 1-, 3-, and 5-year OS in both cohorts (Figures 7(b) and 7(c)). Of importance, these results indicated that the nomogram had the potential to develop into a quantitative tool to predict the prognosis of LGG patients.
3.6. Correlation between the m6A-Related Prognostic Signature and the Immune Landscape of LGG Microenvironment
In the TCGA cohort, the high-risk group showed significantly higher immune, stroma, and ESTIMATE scores and lower tumor purity compared with the low-risk group (Figure 8(a)). Moreover, the risk score was correlated with the expression of immune checkpoints, including PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, B7H3, and IDO1 (Figure 8(b)). Besides, different extents of immune cell infiltrations were observed in the high-risk group with lower abundance of activated NK cells, monocytes, resting mast cells, activated mast cells, and eosinophils but higher abundance of CD4+ memory resting T cells, M1-type macrophages, resting mast cells, and neutrophils (Figure 8(c)). These results confirmed a tight correlation between the m6A-related prognostic signature and the immune landscape of the LGG microenvironment.
As more and more m6A RNA methylation regulators have been identified, the important roles played by m6A modification in cancers are being gradually unveiled. At present, the roles of individual genes in tumorigenesis of glioma via mediating m6A modification are the focus of intense research efforts. METTL3 regulates the proliferation, migration, and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway . ALKBH5 maintains tumorigenicity of GBM stem-like cells by sustaining FOXM1 expression and cell proliferation program . Inhibiting the expression of FTO enhances the effect of temozolomide on glioma . According to most relevant researches, no distinction was made for the different WHO grades of glioma, or GBM tended to receive more attention. Although LGG has a relatively low degree of malignancy compared with GBM, the high rate of postoperative recurrence and malignant progression should not be underestimated. Given the heterogeneity between LGG and GBM in tumor biological behavior, there is a need to comprehensively evaluate the prognostic role of m6A RNA methylation regulators in LGG.
In this study, a total of 36 m6A RNA methylation regulators were selected, most of which were found to be differentially expressed in LGG tissues compared with normal brain tissues and GBM tissues. There were large differences in the expression levels of m6A RNA methylation regulators even between WHO grade II and III. The differential expression profiles inspired us to further explore the role of m6A RNA methylation regulators in LGG. Afterwards, three clusters of LGG patients were identified through consensus cluster analysis based on the expression levels of 36 m6A RNA methylation regulators. The PCA and survival analysis confirmed the significant discrimination among the three clusters. Cluster 3 had worse survival outcomes and was closely related to malignancy-related biological processes and signaling pathways. Subsequently, an m6A-related prognostic signature was constructed. The Kaplan-Meier curves, ROC curves, and univariant and multivariant Cox regression analyses verified that this prognostic signature performed excellently in prognostic stratification of LGG patients. Furthermore, a nomogram for 1-, 3-, and 5-year OS were established based on the signature-based risk score combining age and 1p19q codeletion status. The C-indices and calibration plots suggested that this nomogram has the potential to be an effective assessment tool to identify personalized mortality risk for LGG patients. Finally, we uncovered the differential immune landscape between risk subgroups by comparing the immune, stromal, and ESTIMATE scores; tumor purity; expression levels of immune checkpoints; and abundance of immune cells.
The m6A-related prognostic signature contained nine m6A RNA methylation regulators, seven of which are “readers” (ZCCHC4, SETD2, IGF2BP2, IGF2BP3, YTHDF2, EIF3H, and YTHDC1) and the other two are “writers” (RBM15) and “erasers” (ALKBH3), respectively. Among these critical genes, several have been investigated to be associated with glioma. SETD2, a highly mutated gene, contributes to the tumorigenesis of high-grade glioma . IGF2BP3 promotes glioma cell migration by enhancing the translation of RELA/p65 . YTHDF2, phosphorylated and stabilized by EGFR/SRC/ERK, is required for cholesterol dysregulation, cell proliferation, invasion, and tumorigenesis of GBM . However, there have been few reports focusing on LGG. Little information has been available regarding whether the m6A RNA methylation regulators contribute to the heterogeneity between LGG and GBM in tumor biological behavior, drug resistance, and prognosis. Therefore, we expect that our findings help to identify the prognostic m6A RNA methylation regulators in LGG and provide insights into their potential roles in LGG tumorigenesis and progression.
Tumor microenvironment (TME) has been identified as an essential regulatory role in the occurrence and progression of tumors . It has been reported that LGG patients with high immune scores or high stromal scores had a poor prognosis [30–32]. Emerging evidence confirmed that the dysregulation of m6A RNA methylation regulators contributes to the heterogeneity of TME [12, 33, 34]. Up to now, the impact of m6A RNA methylation regulators on the immune landscape of the LGG microenvironment remains unclear. Firstly, this study found that LGG patients in the high-risk group had higher immune scores, higher stromal scores, higher ESTIMATE scores, and lower tumor purity than those in the low-risk group. Nowadays, immunotherapy, represented by immune checkpoint blockades (PD-1/L1), has been one of the most promising treatment strategies against various cancers. Interestingly, a positive correlation between the risk score and expression level of immune checkpoints was discovered. Thus, the risk stratification based on the m6A-related prognostic signature might help predict the efficacy of immune checkpoint blockades. As a critical part of the complex TME, immune cells have been identified to be associated with the tumor biological behavior and prognosis [35–37]. The results showed a lower abundance of activated NK cells, a major tumor killer cell type, in the high-risk group. Taken together, our findings suggested that m6A RNA methylation regulators partly participate in TME regulation of LGG and might provide new insights into the immunotherapy for LGG.
Undeniably, some limitations of our study should be pointed out. Firstly, the m6A-related prognostic signature was constructed and validated with retrospective data from public databases. Using prospective data to assess its clinical utility would be more convincing. Secondly, this study only focused on the transcriptome data, other data types like methylation, single nucleotide polymorphism (SNP), copy number variation (CNV), and protein level were not covered. In addition, due to the lack of experimental evidences, this study was not able to assess the role and molecular mechanism of individual regulators in depth. Further in vivo and in vitro experiments are essential to explore the regulatory mechanism of m6A RNA methylation regulators in LGG.
All in all, the present study systematically investigated the expression pattern, prognostic value, and effect on the immune landscape of m6A RNA methylation regulators in LGG. We identified three clusters that stratified the prognosis of LGG patients. An m6A-related risk signature was capable to precisely predict the prognosis of LGG patients and was correlated with the immune landscape of the LGG microenvironment. We hope that our findings provide comprehensive evidence for subsequent research about m6A modification in LGG.
Publicly available datasets were analyzed in this study. This data can be found here: The data analyzed in this study can be acquired in the TCGA (https://portal.gdc.cancer.gov/), CGGA (http://www.cgga.org.cn/) and GTEx (https://www.gtexportal.org) websites.
Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.
This study was supported by the National Natural Science Foundation of China (No.81974390).
Supplementary Figure S1: consensus clustering analysis of 36 m6A RNA methylation regulators. (a, b) Relative change in area under CDF curve and consensus clustering CDF for . (c) Tracking plot for . (d) Consensus clustering matrix for . (Supplementary Materials)
- Q. T. Ostrom, H. Gittleman, P. Farah et al., “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010,” Neuro-oncology, vol. 15, Supplement 2, pp. ii1–ii56, 2013.
- W. J. Zeng, Y. L. Yang, Z. Z. Liu et al., “Integrative analysis of DNA methylation and gene expression identify a three-gene signature for predicting prognosis in lower-grade gliomas,” Cellular physiology and biochemistry, vol. 47, no. 1, pp. 428–439, 2018.
- The Cancer Genome Atlas Research Network, “Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas,” The New England journal of medicine, vol. 372, no. 26, pp. 2481–2498, 2015.
- K. D. Meyer, Y. Saletore, P. Zumbo, O. Elemento, C. E. Mason, and S. R. Jaffrey, “Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons,” Cell, vol. 149, no. 7, pp. 1635–1646, 2012.
- D. Dominissini, S. Moshitch-Moshkovitz, S. Schwartz et al., “Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq,” Nature, vol. 485, no. 7397, pp. 201–206, 2012.
- B. S. Zhao, I. A. Roundtree, and C. He, “Post-transcriptional gene regulation by mRNA modifications,” Nature reviews Molecular cell biology, vol. 18, no. 1, pp. 31–42, 2017.
- X. Wang, Z. Lu, A. Gomez et al., “N6-methyladenosine-dependent regulation of messenger RNA stability,” Nature, vol. 505, no. 7481, pp. 117–120, 2014.
- L. P. Vu, B. F. Pickering, Y. Cheng et al., “The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells,” Nature medicine, vol. 23, no. 11, pp. 1369–1376, 2017.
- M. Chen, L. Wei, C. T. Law et al., “RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2,” Hepatology, vol. 67, no. 6, pp. 2254–2270, 2018.
- X. Zhou, J. Han, X. Zhen et al., “Analysis of genetic alteration signatures and prognostic values of m6A regulatory genes in head and neck squamous cell carcinoma,” Frontiers in Oncology, vol. 10, p. 718, 2020.
- N. Xu, J. Chen, G. He, L. Gao, and D. Zhang, “Prognostic values of m6A RNA methylation regulators in differentiated thyroid carcinoma,” Journal of Cancer, vol. 11, no. 17, pp. 5187–5197, 2020.
- X. He, L. Tan, J. Ni, and G. Shen, “Expression pattern of m(6)A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer,” Cancer Gene Therapy, vol. 28, 2021.
- X. Wu, X. Zhang, L. Tao, X. Dai, and P. Chen, “Prognostic value of an m6A RNA methylation regulator-based signature in patients with hepatocellular carcinoma,” BioMed research international, vol. 2020, Article ID 2053902, 11 pages, 2020.
- Y. Su, J. Huang, and J. Hu, “m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gastric cancer,” Frontiers in Oncology, vol. 9, 2019.
- Q. Wang, J. Armenia, C. Zhang et al., “Unifying cancer and normal RNA sequencing data from different sources,” Scientific data, vol. 5, 2018.
- T. Sun, R. Wu, and L. Ming, “The role of m6A RNA methylation in cancer,” Biomedicine & Pharmacotherapy, vol. 112, 2019.
- S. Zaccara, R. J. Ries, and S. R. Jaffrey, “Reading, writing and erasing mRNA methylation,” Nature reviews Molecular cell biology, vol. 20, no. 10, pp. 608–624, 2019.
- M. D. Wilkerson and D. N. Hayes, “ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking,” Bioinformatics, vol. 26, no. 12, pp. 1572-1573, 2010.
- M. E. Ritchie, B. Phipson, Y. H. Di Wu, C. W. Law, W. Shi, and G. K. Smyth, “limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic acids research., vol. 43, no. 7, 2015.
- F. E. Harrell Jr., K. L. Lee, and D. B. Mark, “Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors,” Statistics in medicine, vol. 15, no. 4, pp. 361–387, 1996.
- K. Yoshihara, M. Shahmoradgoli, E. Martínez et al., “Inferring tumour purity and stromal and immune cell admixture from expression data,” Nature Communications, vol. 4, no. 1, 2013.
- A. M. Newman, C. L. Liu, M. R. Green et al., “Robust enumeration of cell subsets from tissue expression profiles,” Nature Methods, vol. 12, no. 5, pp. 453–457, 2015.
- J. W. Ji, Y. D. Zhang, Y. J. Lai, and C. G. Huang, “Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway,” European review for medical and pharmacological sciences, vol. 24, no. 7, pp. 3818–3828, 2020.
- S. Zhang, B. S. Zhao, A. Zhou et al., “m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program,” Cancer cell, vol. 31, no. 4, 2017.
- L. Xiao, X. Li, Z. Mu et al., “FTO inhibition enhances the antitumor effect of temozolomide by targeting MYC-miR-155/23a cluster-MXI1 feedback circuit in glioma,” Cancer research, vol. 80, no. 18, pp. 3945–3958, 2020.
- A. M. Fontebasso, J. Schwartzentruber, D. A. Khuong-Quang et al., “Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas,” Acta Neuropathologica, vol. 125, no. 5, pp. 659–669, 2013.
- S. Bhargava, A. Visvanathan, V. Patil et al., “IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65,” Oncotarget, vol. 8, no. 25, pp. 40469–40485, 2017.
- R. Fang, X. Chen, S. Zhang et al., “EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma,” Nature communications, vol. 12, no. 1, 2021.
- D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
- J. Galon, B. Mlecnik, G. Bindea et al., “Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours,” The Journal of pathology, vol. 232, no. 2, pp. 199–209, 2014.
- W. H. Fridman, F. Pagès, C. Sautès-Fridman, and J. Galon, “The immune contexture in human tumours: impact on clinical outcome,” Nature reviews Cancer, vol. 12, no. 4, pp. 298–306, 2012.
- X. Deng, D. Lin, X. Zhang et al., “Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas,” Journal of Cellular Physiology, vol. 235, no. 10, pp. 7321–7331, 2020.
- L. Yi, G. Wu, L. Guo, X. Zou, and P. Huang, “Comprehensive analysis of the PD-L1 and immune infiltrates of m6A RNA methylation regulators in head and neck squamous cell carcinoma,” Molecular Therapy - Nucleic Acids, vol. 21, pp. 299–314, 2020.
- Y. Liu, G. Cheng, Z. Huang et al., “Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma,” Cell Death & Disease, vol. 11, no. 7, 2020.
- B. Weenink, M. van Brakel, R. Wijers, P. A. E. Sillevis Smitt, P. J. French, and R. Debets, “Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients,” Journal of neuro-oncology, vol. 144, no. 1, pp. 79–87, 2019.
- S. Han, C. Zhang, Q. Li et al., “Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma,” British journal of cancer, vol. 110, no. 10, pp. 2560–2568, 2014.
- M. Zhang, X. Wang, X. Chen, Q. Zhang, and J. Hong, “Novel immune-related gene signature for risk stratification and prognosis of survival in lower-grade glioma,” Frontiers in Genetics, vol. 11, p. 363, 2020.
Copyright © 2021 Jianglin Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.